|
OncoGenex Increases Economic Interest in Lead Cancer Drug OGX-011
04 July 2008
Under the amended agreement between OncoGenex and Isis, the former will be solely responsible for all future development activities related to OGX-011.
|
|
|
|
MS Drug Development Agreement Based on WEHI's Medicinal Chemistry
03 July 2008
Research conducted at the institute has contributed to a major licensing agreement signed between Bionomics and Merck Serono.
|
|
|
|
Bayer HealthCare and Maxygen Announce Hematology Agreement
03 July 2008
The $120 million transaction includes license to Maxygen’s novel biotechnology research platform.
|
|
|
|
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
02 July 2008
AstraZeneca and Palatin amend their collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.
|
|
|
|
Galapagos Signs new Compound Management Agreement with Sepracor
01 July 2008
Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library.
|
|
|
|
Cellumen to Collaborate with the NCTR of the FDA to Apply Cellular Systems Biology to Predictive Toxicology
01 July 2008
Cellumen will use its proprietary CellCiphr® toxicity risk assessment technology to profile blinded samples of known liver toxicity compounds.
|
|
|
|
Millipore Unveils Expanded Drug Discovery Development Facility
30 June 2008
The $3.4 million expansion will enable Millipore to keep pace with the growth of its worldwide drug discovery and development business.
|
|
|
|
Eden Biodesign Confirms Research Triangle Park Facility
26 June 2008
The Company expands US operation to offer a range of cell line/strain development and early process development services.
|
|
|
|
FDA Approves Quark IND for DGFi, an siRNA therapeutic based on Silence Therapeutics’ Proprietary Chemistry
26 June 2008
Quark to develop drug candidate for prevention and treatment of delayed graft function in kidney transplantation.
|
|
|
|
GWC Technologies Obtains License for Versatile Label-Free Array Surface from WARF
26 June 2008
The license will allow GWC’s imaging systems to generate reliable data using ‘carbon-on-metal surface technology.
|
|
|
|
Luna nanoWorks' MRI Contrast Agent Breakthrough Published in Journal of Medicinal Chemistry
26 June 2008
The new contrast agent includes gadolinium which is encapsulated within an extremely stable carbon nanosphere that allows safe, extended residence within the body.
|
|
|
|
VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo
25 June 2008
VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects.
|
|
|
|
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602
24 June 2008
PSN602 is an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity.
|
|
|
|
New Data Further Strengthens Case for Microdosing in Drug Development
24 June 2008
The EUMAPP consortium presented preliminary results from the 30-month, €2m project at the EUFEPS Conference.
|
|
|
|
Galapagos Announces Milestone Payment of €0.8 Million in Osteoarthritis Alliance with GlaxoSmithKline
23 June 2008
Galapagos has reached two new milestones in its multi-year drug discovery alliance initiated in June 2006 with GSK.
|
|
|
|
Illumina Announces Mitsubishi Chemical Safety Institute as Japan's First Certified Genetic Analysis Service Provider
20 June 2008
The Institute offers its customers whole-genome and targeted-genotyping services using Illumina's Infinium® and GoldenGate® Assays.
|
|
|
|
Celleron Therapeutics Establishes in Oxford, UK
20 June 2008
The Company has two oncology programmes in clinical development, a strong pre-clinical pipeline and a targeting biomarker capability, CancerNav™.
|
|
|
|
Idealp-Pharma Launches ‘Hit-To-Candidate’ Services
20 June 2008
Idealp-Pharma is launching fully integrated drug discovery and preclinical development services to speed up partner’s and client’s small molecules programs.
|
|
|
|
Mass Spectrometry Test makes Cheating with Drugs in Sports Easier to Detect
19 June 2008
A new mass spectrometry test can help sports anti-drug doping officials to detect whether an athlete has used drugs that boost naturally occurring steroid levels.
|
|
|
|
Immtech Pharmaceuticals and Beijing Capital Medical University will Provide Contract Research Services in China
19 June 2008
The joint venture will provide services in drug discovery research for companies and organizations seeking to develop pharmaceutical products and biologics.
|
|
|
|
U.S. EPA Licenses Simulations Plus’ Admet Predictor™ Software
18 June 2008
Agency licenses both toxicity and new Enslein metabolism modules.
|
|
|
|
Corning Announces Significant Milestone in High-Throughput Label-Free Screening for Drug Development
13 June 2008
Scientists performed two 100,000-compound screens in high throughput using Corning® Epic® System.
|
|
|
|
Pfizer Report Demonstrates Value of Conducting Virtual Studies of Drug-Drug Interactions
12 June 2008
Scientists have used the Simcyp Simulator to predict the extent of drug-drug interactions for maraviroc, which is used in the treatment of HIV.
|
|
|
|
Pfizer and UCSF Form Alliance to Advance a Broad Range of Research
12 June 2008
Pfizer, Inc. and UCSF have launched a collaboration to span many disciplines, several UC campuses and multiple Pfizer research units.
|
|
|
|
Nuevolution Announces Drug Discovery Alliance with Lexicon Pharmaceuticals
12 June 2008
Nuevolution's Chemetics® drug discovery technology will be applied to identify small molecule lead compounds against Lexicon drug targets.
|
|
|
|
Avid Radiopharmaceuticals Initiates First Phase II Trial of Compound for Imaging Alzheimer’s Disease
10 June 2008
Study of 18F-AV-45 for PET imaging of Amyloid Plaque begins enrolling patients.
|
|
|